Benserazide hydrochloride
98%
- Product Code: 98231
Alias:
Benserazide Hydrochloride
CAS:
14919-77-8
| Molecular Weight: | 293.7 g./mol | Molecular Formula: | C₁₀H₁₅N₃O₅HCl |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD00078571 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | room temperature, away from light |
Product Description:
Benserazide hydrochloride is primarily used in the treatment of Parkinson's disease. It is often administered in combination with levodopa to enhance the therapeutic effects of the latter. By inhibiting the enzyme aromatic L-amino acid decarboxylase (AADC) in peripheral tissues, it prevents the premature conversion of levodopa to dopamine outside the brain. This ensures a higher concentration of levodopa reaches the central nervous system, where it is converted to dopamine, thereby alleviating the motor symptoms associated with Parkinson's disease. This combination therapy helps to reduce the dosage of levodopa required, minimizing side effects such as nausea and cardiovascular issues. Additionally, it improves the overall management of symptoms, providing better control of tremors, rigidity, and bradykinesia in patients.
Product Specification:
| Test | Specification |
|---|---|
| PURITYHPLC | 98-100 |
| APPEARANCE | White fiber |
| INFRARED SPECTRUM | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 1.000 | 10-20 days | €18.47 |
+
-
|
| 5.000 | 10-20 days | €83.10 |
+
-
|
| 25.000 | 10-20 days | €249.57 |
+
-
|
| 100.000 | 10-20 days | €948.17 |
+
-
|
Benserazide hydrochloride
Benserazide hydrochloride is primarily used in the treatment of Parkinson's disease. It is often administered in combination with levodopa to enhance the therapeutic effects of the latter. By inhibiting the enzyme aromatic L-amino acid decarboxylase (AADC) in peripheral tissues, it prevents the premature conversion of levodopa to dopamine outside the brain. This ensures a higher concentration of levodopa reaches the central nervous system, where it is converted to dopamine, thereby alleviating the motor symptoms associated with Parkinson's disease. This combination therapy helps to reduce the dosage of levodopa required, minimizing side effects such as nausea and cardiovascular issues. Additionally, it improves the overall management of symptoms, providing better control of tremors, rigidity, and bradykinesia in patients.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
€0.00
€0.00
Total :